SHORT COMMUNICATIONS

Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure. Ken-ichi Fujita, Yu Sunakawa, Keisuke Miwa, Yuko Akiyama, Minako Sugiyama, Kaori Kawara, Hiroyo Ishida, Keishi Yamashita, Keiko Mizuno, Shigehira Saji, Wataru Ichikawa, Wataru Yamamoto, Fumio Nagashima, Toshimichi Miya, Masaru Narabayashi, Yuichi Ando, Takashi Hirose, and Yasutsuna Sasaki .... 161

Altered Cytochrome P450 Expression in Mice during Pregnancy. Kwi Hye Koh, Hui Xie, Ai-Ming Yu, and Hyunyoung Jeong .................. 165


ARTICLES


Human CYP2S1 Metabolizes Cyclooxygenase- and Lipoxygenase-Derived Eicosanoids. Peter Bui, Satoshi Imaiunji, Sudheer Reddy Beedanagari, Srinvasa T. Reddy, and Oliver Hankinson . . . 180

CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis. Yi Jin, Markus Zollinger, Hubert Borell, Alfred Zimmerlin, and Christopher J. Patten ......................... 191

Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways. Markus Zollinger, Hans-Peter Gschwind, Yi Jin, Claudia Sayer, Frédéric Zécri, and Stefan Hartmann .......... 199

Glutaredoxin and Thioredoxin Can Be Involved in Producing the Pharmacologically Active Metabolite of a Thiopopyridine Antiplatelet Agent, Prasugrel. Katsunobu Hagiwara, Miho Kazui, Atsushi Kurihara, Kazuishi Kubota, and Toshikiko Ikeda.......................... 208

Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans. Cecilia Renzulli, Mike Nash, Mark Wright, Steven Thomas, Stefano Zamuner, Mario Pellegrato, Paolo Bettinelli, and Gary Boyle ........ 215

Metabolism and Disposition of 14C-Labeled Peliglitzar in Humans. Lifei Wang, Carey Munscik, Sean Chen, Samuel Bonacorsi, Peter T. Cheng, W. Griffith Humphreys, and Donglu Zhang .... 228


Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. Martin N. Fransson, Henrik Grén, Jan-Eric Litton, and Lena E. Friberg ............ 247

Tissue Distribution and Elimination of [14C]Apixaban in Rats. Lifei Wang, Kan He, Brad Maxwell, Scott .... 249

Continued on next page
Brain Tissue Binding of Drugs: Evaluation and Validation of Solid Supported Porcine Brain Membrane Vesicles (TRANSIL) as a Novel High-Throughput Method. Raffaele Longhi, Silvia Corbioli, Stefano Fontana, Federica Vincenti, Simone Braggio, Lydia Helmdach, Jürgen Schiller, and Hinnerk Boriss

Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors. Jin Zhou, Timothy S. Tracy, and Rory P. Remmel

Ethanol Induction of CYP2A5: Permissive Role for CYP2E1. Yongke Lu, Jian Zhuge, Defeng Wu, and Arthur I. Cederbaum

Identification and Validation of Novel Human Pregnan X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening. Yongmei Pan, Linhao Li, Gregory Kim, Sean Ekins, Hongbing Wang, and Peter W. Swaan

Inactivation of Cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a Thiophene-Containing Anticancer Drug. Hsia-lien Lin, Haoming Zhang, Christine Medower, Paul F. Hollenberg, and William W. Johnson

ERRATUM
Correction to “Identification of Clinically Utilized Drugs that Activate Pregnan X Receptors”.

Downloaded from dmd.aspetjournals.org at ASPET Journals on April 7, 2017

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Molecular modeling showing the binding of OSI-930 in the active sites of P450 3A4 (A) and P450 3A5 (B). See the article by Lin et al. on page 345 of this issue.